AzTrials
AzTrials

Dermatitis, AtopicNCT07887867

A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies

An observational study of Dermatitis, Atopic, run by Pfizer.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as "advanced" therapies. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dermatitis, Atopic
What is being tested?
abrocitinib
How many people
120 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 31 Aug 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: severe atopic dermatitis adult (>=18 years) patients of both sexes who, according to clinical practice, have been switched directly to abrocitinib 100 mg or 200 mg after a maximum of 2 previous advanced therapies for the treatment of severe atopic dermatitis, including biologics (i.e., dupilumab, lebrikizumab, tralokinumab) and/or JAKis (i.e., baricitinib, upadacitinib).

Who may be able to join

  • >=18 years of age on date of the enrolment visit
  • Severe atopic dermatitis diagnosed in accordance with guidelines used per clinical practice
  • Patients have agreed to switch from a prior advanced therapy for severe AD (i.e., dupilumab, lebrikizumab, tralokinumab, baricitinib, or upadacitinib) to abrocitinib 100 mg or 200 mg, based on the Investigator's clinical judgment and independent of study participation.
  • Evidence of a personally signed and dated informed consent document
  • Exclusion Criterion: Patients treated with more than 2 advanced therapies for AD, either biologics or JAKis

Who cannot join

None listed.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Pfizer CT.gov Call Center contact

1-800-718-1021

ClinicalTrials.gov_Inquiries@pfizer.com

About this study

Official title: A REAL-WORLD RETRO-PROSPECTIVE SINGLE COHORT STUDY EVALUATING THE EFFECTIVENESS OF ABROCITINIB (100/200 MG) IN PATIENTS AFFECTED BY SEVERE ATOPIC DERMATITIS SWITCHED PER CLINICAL PRACTICE FROM OTHER ADVANCED THERAPIES, INCLUDING BIOLOGICS AND/OR OTHER JAK INHIBITORS - ABRO-SWITCH

The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as "advanced" therapies.

Atopic dermatitis is a long-lasting skin condition that causes the skin to become inflamed, dry, and itchy.

Read more

This study is seeking participants who:

  • are 18 years of age or older;
  • have severe atopic dermatitis;
  • have previously been treated with advanced therapies authorised for atopic dermatitis and are moving to abrocitinib (100 mg or 200 mg);
  • have received no more than two authorised advanced therapies for their atopic dermatitis.

All participants will receive study medicine, abrocitinib as part of their usual medical care. The decision to give the study medicine is made by their dermatologist. This decision is independent of participation in the study. Abrocitinib will be taken by mouth at home once daily as prescribed by the treating doctor.

We will examine the experiences of people receiving abrocitinib for up to one year after starting abrocitinib. We will look back at the information up to 6 months before they have started taking abrocitinib. This will help us learn how abrocitinib affects severe atopic dermatitis in people who have moved from other authorised advanced therapies.

Participants will take part in this study for 1 year. During this time, they will have about 5 visits. These visits are a part of their routine care. During the visits, the doctor will assess how severe atopic dermatitis is. Participants may be asked questions about their symptoms and how the condition affects their daily life.

No additional clinic visits, tests, or procedures are required for this study, beyond normal clinical practice.

Being tested
abrocitinib
Keywords
Dermatitis, Atopic; Abrocitinib; Janus Kinase Inhibitors; Pruritus; Quality of Life; Treatment Switching; Real-World Evidence
Medical subject headings
Dermatitis, Atopic, Dermatitis, Pruritus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • abrocitinibDrug

    Abrocitinib administered according to routine clinical practice at doses of 100 mg or 200 mg once daily.

Study groups in NCT07887867
Study groupRoleWhat they receive
Patients switched to abrocitinibAdult patients with severe atopic dermatitis who switched from previous advanced therapies (dupilumab, lebrikizumab, tralokinumab, baricitinib, upadacitinib) to abrocitinib according to routine clinical practice
Receives: Drug: abrocitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) <7

    Measured: Week 24

Secondary outcomes (19)

  1. EASI 90

    Proportion of participants reaching 90% improvement in EASI from baseline

    Measured: Week 4, 12, 24, 52

  2. Change from baseline in Eczema Area and Severity Index (EASI) Score

    Measured: Baseline, Week 4, 12, 24, 52

  3. Change from baseline in Peak Pruritus-Numeric Rating Scale (PP-NRS) Score

    Measured: Baseline, Week 4, 12, 24, 52

  4. Percentage of Participants Achieving PP-NRS <=1

    Measured: Week 4, 12, 24, 52

  5. Change from baseline in Investigator's Global Assessment (IGA) Score

    Measured: Week 4, 12, 24, 52

  6. Percentage of Participants Achieving IGA 0-1

    Measured: Week 4, 12, 24, 52

  7. Change from baseline in Dermatology Life Quality Index (DLQI) Score

    Measured: Week 4, 12, 24, 52

  8. Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score

    Measured: Week 4, 12, 24, 52

  9. Change from baseline in Sleep Disturbance Numeric Rating Scale (SD-NRS) Score

    Measured: Week 4, 12, 24, 52

  10. Percentage of Participants Achieving Minimal Disease Activity (MDA)

    Measured: Week 4, 12, 24, 52

  11. Demographics Characteristics: Percentage of Participants by Age, Gender, Education, Occupation, Family Status

    Measured: Baseline

  12. Number of Participants by Age-at-Onset Category for Atopic Dermatitis

    Age at onset

    Measured: Baseline

  13. Number of Participants by Atopic Dermatitis Phenotype

    Measured: Baselines, Week 4, 12, 24, 52

  14. Number of Participants with Each Difficult-to-Treat Body Area

    Measured: Baseline, Week 4, 12, 24, 52

  15. Clinical Characteristics: Duration of Previous Advanced Therapy Before Switching to Abrocitinib

    Measured: Baseline

  16. Number of participants with Each Atopic Comorbidity

    Measured: Baseline, Week 4,12,24,52

  17. Number of Participants with Each Non-Atopic Comorbidity

    Measured: Baseline, Week 4,12,24,52

  18. Adherence to Abrocitinib

    Percentage of actual vs. expected therapeutic dosages as reported by the participants.

    Measured: Week 4,12, 24, 52

  19. Persistence to Abrocitinib

    Percentage of participants on treatment at week 52.

    Measured: Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Oct 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion1 Oct 2027 (estimated)
  4. Study completion31 Aug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07887867
Sponsor's protocol ID
B7451138
Other IDs
ABRO-SWITCH
Status last verified
Oct 2026
First submitted
29 Sep 2026
Last updated
21 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Questions about this trial

What is this clinical trial studying?

An observational study of Dermatitis, Atopic, run by Pfizer.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving Eczema Area and Severity Index (EASI) <7 (time frame: Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07887867.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in